No benefit of any kind will be received either directly or indirectly by the authors.
Controlled release of neurotrophin-3 from fibrin-based tissue engineering scaffolds enhances neural fiber sprouting following subacute spinal cord injury†
Article first published online: 14 JUL 2009
Copyright © 2009 Wiley Periodicals, Inc.
Biotechnology and Bioengineering
Volume 104, Issue 6, pages 1207–1214, 15 December 2009
How to Cite
Johnson, P. J., Parker, S. R. and Sakiyama-Elbert, S. E. (2009), Controlled release of neurotrophin-3 from fibrin-based tissue engineering scaffolds enhances neural fiber sprouting following subacute spinal cord injury. Biotechnol. Bioeng., 104: 1207–1214. doi: 10.1002/bit.22476
- Issue published online: 22 OCT 2009
- Article first published online: 14 JUL 2009
- Accepted manuscript online: 14 JUL 2009 12:00AM EST
- Manuscript Accepted: 9 JUL 2009
- Manuscript Revised: 30 JUN 2009
- Manuscript Received: 14 MAY 2009
- NIH-NINDS. Grant Number: R01 NS051454
- nerve regeneration;
- growth factors;
- delivery system
This study investigated whether delayed treatment of spinal cord injury with controlled release of neurotrophin-3 (NT-3) from fibrin scaffolds can stimulate enhanced neural fiber sprouting. Long Evans rats received a T9 dorsal hemisection spinal cord injury. Two weeks later, the injury site was re-exposed, and either a fibrin scaffold alone, a fibrin scaffold containing a heparin-based delivery system with different concentrations of NT-3 (500 and 1,000 ng/mL), or a fibrin scaffold containing 1,000 ng/mL of NT-3 (no delivery system) was implanted into the injury site. The injured spinal cords were evaluated for morphological differences using markers for neurons, astrocytes, and chondroitin sulfate proteoglycans 2 weeks after treatment. The addition of 500 ng/mL of NT-3 with the delivery system resulted in an increase in neural fiber density compared to fibrin alone. These results demonstrate that the controlled release of NT-3 from fibrin scaffolds can enhance neural fiber sprouting even when treatment is delayed 2 weeks following injury. Biotechnol. Bioeng. 2009; 104: 1207–1214. © 2009 Wiley Periodicals, Inc.